Form 4: Teladoc Health Executive Adam C. Vandervoort Reports Stock Transactions
SEC Form 4 Filing
Teladoc Health's Chief Legal Officer, Adam C. Vandervoort, reported the acquisition of shares through vesting of stock units and the sale of shares to cover tax obligations.
Summary
- Adam C. Vandervoort, Chief Legal Officer of Teladoc Health, reported several transactions involving the company's stock.
- On November 29, 2024, Vandervoort acquired 1,505 shares of common stock through the vesting of performance stock units.
- He also acquired 1,881 and 4,418 shares of common stock through the vesting of restricted stock units on the same day.
- On December 2, 2024, Vandervoort sold 4,004 shares of common stock at a price of $11.927 per share.
- These sales were to cover tax withholding obligations related to the vesting of his stock unit awards.
- Following these transactions, Vandervoort beneficially owns 50,050 shares of Teladoc Health common stock.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of stock transactions by an executive, which is neither positive nor negative for the company's performance. It is a neutral event.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is common practice for publicly traded companies. It provides transparency into the trading activities of insiders.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies in the US, and Teladoc's filing is consistent with these requirements.
- The vesting schedules and tax-related sales are typical for executive compensation packages in the technology and healthcare sectors.
- Other companies in the telehealth space, such as Amwell and Hims & Hers, also have similar insider transaction filings.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they represent a small portion of the total outstanding shares.
- The sale of shares by the executive may have a slight downward pressure on the stock price, but this is likely to be minimal.
Key Dates
| Date | Description |
|---|---|
| 03/01/2022 | Grant date of 22,571 restricted stock units, vesting over time. |
| 03/03/2023 | Grant date of 53,013 restricted stock units, vesting over time. |
| 03/01/2024 | The reporting person earned 18,067 performance stock units, vesting over time. |
| 11/29/2024 | Vesting of performance and restricted stock units, resulting in share acquisitions. |
| 12/02/2024 | Sale of 4,004 shares to cover tax obligations. |
| 12/03/2024 | Date of signature on the Form 4 filing. |
Keywords
Teladoc Health, TDOC, stock transactions, insider trading, Form 4, stock units, vesting, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.